10th Biennial Symposium
19-23 July 2017
Gothenburg, Sweden
Elite Park Avenue Hotel

Final Program
Board of Directors 2015-2017

President
Peter Weller, MD
Harvard Medical School, Beth Israel Deaconess Medical School
Boston, MA
United States

President Elect
Bruce S. Bochner, MD
Northwestern University
Chicago, IL
United States

Immediate Past President
Hans-Uwe Simon, MD, PhD
University of Bern
Bern, Switzerland

Secretary-Treasurer
Hirohito Kita, MD
Mayo Clinic Rochester
Rochester, MN
United States

Scientific Program Director
Marie Carlson, MD, PhD
Uppsala University
Uppsala, Sweden

Trainee Board Member
Neda Farahi, BSc, PhD
University of Cambridge
Cambridge, United Kingdom

At-Large Directors
Seema S. Aceves, MD, PhD
University of California San Diego
San Diego, CA
United States

Allison D. Fryer, PhD
Oregon Health and Science University
School of Medicine
Portland, OR
United States

Patricia C. Fulkerson, MD, PhD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
United States

James J. Lee, PhD
Mayo Clinic Arizona
Scottsdale, AZ
United States

Kenji Matsumoto, MD, PhD
National Research Institute
Tokyo, Japan

Josiane S. Neves, PhD
Federal University of Rio de Janeiro
Institute of Biomedical Sciences
Rio de Janeiro, Brazil

Marc Rothenberg, MD, PhD
Cincinnati Children’s Hospital
Cincinnati, OH
United States

Florence Roufosse, MD, PhD
Hospital Erasme (ULB)
Brussels, Belgium

Lisa A. Spencer, PhD
Harvard Medical School, Beth Israel Deaconess Medical School
Boston, MA
United States

Andrew Wardlaw, MD
Glenfield Hospital
Leicester, United Kingdom
Table of Contents

Welcome ........................................................................................................................................... 3
Acknowledgements ............................................................................................................................. 4
General Information ............................................................................................................................ 5
Scientific Program ............................................................................................................................... 6
Awards ................................................................................................................................................... 15
In Memoriam ........................................................................................................................................ 16
Invited Speaker Abstracts ..................................................................................................................... 18
Oral Abstracts ....................................................................................................................................... 28
Poster Session Abstracts ...................................................................................................................... 45
Participant List ....................................................................................................................................... 71
Welcome

Welcome fellow eosinomaniacs! After years of planning, we are excited to host you in Gothenburg for the 10th Biennial Symposium of the International Eosinophil Society, Inc. The 2017 meeting, just like prior ones, should be an ideal opportunity for each of us to explore interests, ideas and collaborations in an environment of openness and collegiality.

For those of you that have attended prior meetings, the structure and format of the meeting should feel familiar, but for those of you attending for the first time, here is a brief overview. Tuesday’s pre-conference meeting will be devoted to the 8th in a series of clinically oriented workshops. The workshop organized by Amy Klion, will focus on biologic therapies for eosinophilic disorders. The main meeting will open on Tuesday evening with a reception that will include a talk by Per Venge. Sessions beginning Wednesday morning and continuing until midday Sunday, will highlight the latest advances in basic and clinical research, presented as state-of-the-art talks by leaders in the field, cutting-edge lectures on new findings, and oral presentations and posters taken from over 90 submitted abstracts. There will be plenty of opportunities for discussion during the two poster sessions, and prizes will be given to trainees at the beginning of the last day for best posters and oral presentations.

Finally, we would like to extend our extreme gratitude to our corporate and non-profit sponsors and volunteers, without whom this meeting would never have been possible; to Steve Ackerman, whose efforts once again resulted in our ability to offer travel grants to trainees; for the time and effort of our colleagues among the IES leadership and others who served on the meeting’s various committees; and to Kate Filipiak and Kris Heijnen at EDI, whose guidance, professionalism, patience, and skills insured the successful organization of this meeting and made the process such a pleasure.

We hope you enjoy the meeting!

Peter Weller
President

Marie Carlson
Scientific Program Director

Christine Wennerås
Scientific Program Director
# Acknowledgements

IES thanks the following partners for their support of the 10th Biennial Symposium

<table>
<thead>
<tr>
<th>Gold Supporter</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA Respiratory</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Silver Supporters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AstraZeneca</strong></td>
</tr>
<tr>
<td>Diagnostics Development</td>
</tr>
<tr>
<td><strong>GlaxoSmithKline</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bronze Supporters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Allakos</strong></td>
</tr>
<tr>
<td><strong>Apfed</strong> (American Partnership for Eosinophilic Disorders)</td>
</tr>
<tr>
<td><strong>CURED</strong></td>
</tr>
<tr>
<td><strong>Knopp Biosciences</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Additional Support</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Novartis Institutes for BioMedical Research, Inc.</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Society Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Academy of Allergy, Asthma &amp; Immunology</td>
</tr>
<tr>
<td>Society for Leukocyte Biology</td>
</tr>
<tr>
<td>Journal of Leukocyte Biology</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grant Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institutes of Health</td>
</tr>
</tbody>
</table>

Funding for this conference was made possible [in part] by 1 R13 AI 131485 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
General Information

Swedish Coffee Breaks
Coffee breaks are included in the registration fee for attendees and will be served daily. Coffee will be served outside of the Bankett 2 in the Elite Park Avenue Hotel, please check the Scientific Program for exact times.

Education Sessions
All education sessions will take place in the Bankett 2 located in the Elite Park Avenue Hotel.

Meals
Breakfast and Lunch will be provided and included in your registration fee.

Poster Sessions
All poster sessions will take place in the Bankett 1. An assortment of beverages and appetizers will be served. Poster presenters will stand next to their posters during their session and be available for questions and discussions.

Registration
The registration desk will be located outside of the Bankett 2.

Hours:
Wednesday, 19 July 7:30-19:30
Thursday, 20 July 7:30-12:30
15:00-20:00
Friday, 21 July 7:30-13:00
15:00-20:00
Saturday, 22 July 7:30-13:00
14:00-17:30
Sunday, 23 July 7:30-12:30

Social Events

Welcome Reception and Dinner
Wednesday, 19 July, 18:00-19:30
The welcome reception will be held at the Elite Park Avenue Hotel Conference Center. Refreshments and appetizers will be provided.

Symposium Dinner Event and Boat Ride
Saturday, 22 July, 19:00-23:00
The boat ride will depart at 19:00 from the Lilla Bommen dock. Walking directions from Elite Park Avenue Hotel: Exit hotel and proceed Northwest toward the river along Kungsportsplatsen roughly 20 blocks to dock location. Please see below map for directions or bus location.
Scientific Program

Wednesday, 19 July 2017

RE-TREAD: Progress Towards Meeting the 2012 TREAD Needs in Eosinophilic Research
This workshop was supported in part by funds from the National Institute of Allergy and Infectious Diseases (NIAID).

I. Eosinophil Research: A Status Report

8:30 – 8:40
Introduction and Workshop Agenda – Amy Klion, United States

8:40 – 9:00
Overview of TREAD Objectives – Mike Minnicozzi, United States

II. Where We are Today

Moderator: Hans-Uwe Simon, Switzerland

9:00 - 9:15
Status and Impact of Coding for Eosinophilic Disorders – Kathleen Sable, United States

9:15 - 10:30
Tissue Markers of Eosinophil Pathogenesis
Histopathology – Margaret Collins, United States
Granule proteins/EETs – Gerald Gleich, United States
Omics – Marc Rothenberg, United States

10:30 - 11:00
Biomarkers in rare eosinophilic diseases
Biomarkers – Joe Arron, United States
Patient-reported outcomes – Paneez Khoury, United States

11:00 - 11:15 Coffee Break

11:15 - 11:45
Mechanisms of Eosinophil Pathogenesis
Animal models – Elizabeth Jacobsen, United States
Granule proteins – Lisa Spencer, United States

11:45 - 12:00
Patient Registries for Rare Eosinophilic Disorders
The French experience – Jean-Emmanuel Kahn, France

12:00 – 13:00 Lunch

13:00 - 13:30
Clinical Trials in Rare Eosinophilic Disorders
What we can learn from rare diseases – Amy Klion, United States
Combining clinical and mechanistic studies – Mike Wechsler, United States

14:00 - 14:30
Therapeutic Agents for Rare Eosinophilic Disorders
Mepolizumab – Jonathan Steinfeld, United States
Dexpramipexole – Calman Prussin, United States
Scientific Program

Wednesday, 19 July 2017

III. Where Do We Go From Here?

14:00 - 14:30
Research opportunities in rare diseases – Rashmi Gopal-Srivastava, United States

14:30 – 16:00
Prioritization of unmet needs and identification of action items
Moderators: Bruce Bochner, United States and Florence Roufosse, Belgium

Welcome and Reception

17:00 - 17:20
Welcome – Peter Weller, United States; Marie Carlson, Sweden; and Christine Wennerås, Sweden

17:20 - 18:00
Eosinophils during two decades: An old friend in new clothes? – Per Venge, Sweden

18:00 - 19:30
Welcome Reception – Elite Park Avenue Hotel Conference Center

Thursday, 20 July 2017

Session 1: Eosinophils in Host Pathogen Defense

Moderators: Helene Rosenberg, United States and Christine Lingblom, Sweden

8:30-9:00
State-of-the-Art: The eosinophils in anti-pathogen host defense – Helene Rosenberg, United States

9:00-9:30
Cutting Edge: Eosinophils and aspergillus fumigatus infection: a DNA trap release story – Josiane Neves, Brazil

9:30-9:45
Abstract Speaker: PIN1 null eosinophils show impaired differentiation and survival after TLR7 signaling – Zhong-Jian Shen, United States

9:45-10:00
Abstract Speaker: Phenotypic and functional changes in eosinophils may promote antiviral responses in hosts with allergic asthma – Ali Samarasinghe, United States

10:00-10:30 – Coffee Break

Session 2: Intestinal Eosinophils – What Regulates Them and What Do They Regulate?

Moderators: Steve Ackerman, United States and Maria Lampinen, Sweden

10:30-11:00
State-of-the-Art: Eosinophils regulate homeostasis of the GI tract – Derek McKay, Canada

11:00-11:30
Cutting Edge: The human intestinal microbiome – Ingegerd Adlerberth, Sweden

11:30-11:45
Abstract Speaker: A novel biased antagonist of the eotaxin-CCR3 pathway in eosinophils – Milica Grozdanovic, United States

11:45-12:00
Abstract Speaker: Aiolos regulates eosinophil migration – Patricia Fulkerson, United States
Scientific Program

Thursday, 20 July 2017

12:00-15:00 - Conference lunch, meetings, networking

Session 3: Eosinophils in the Gut - Cause or Protection in Eosinophilic Esophagitis and Inflammatory Bowel Disorders?

Moderators: Marc Rothenberg, United States and Robert Saalman, Sweden

15:00-15:30
State-of-the-Art: Eosinophils in IBD – healers or destroyers? – Marie Carlson, Sweden

15:30-16:00
Cutting Edge: Pathogenesis of eosinophilic esophagitis – Marc Rothenberg, United States

16:00-16:30
Cutting Edge: The eosinophil in eosinophilic esophagitis: the “cell-in-chief” or simply an “assistant” – Alex Straumann, Switzerland

16:30-16:45
Abstract Speaker: A phenotypically distinct subset of eosinophils is recovered with intestinal intraepithelial leukocytes – Evangeline Cornwell, United States

16:45-17:00
Abstract Speaker: Whole exome resequencing identifies putatively functional rare variants associated with eosinophilic gastroenteritis – Andrew Wardlaw, United Kingdom

17:00-17:30 - Coffee Break

Gleich Award

Moderator: Peter Weller, United States

17:30-18:00
Lung-Resident Eosinophils Represent a Distinct Regulatory Eosinophil Subset – Claire Mesnil, Belgium and Stéfanie Raulier, Belgium

Moderators: Francesca Levi-Schaffer, Isreal, Steve Ackerman, United States, Dagmar Simon, Switzerland, Allison Fryer, United States and Patricia Fulkerson, United States

18:00-20:00
Poster Session I (Mini-Oral Presentations, Poster Walkabouts, Drinks and finger foods)

Oral Poster 1 Benralizumab is a Well Tolerated and Effective treatment for PDGFRA-Negative Hypereosinophilic Syndrome – Fei Li Kuang

Oral Poster 2 Eosinophil Peroxidase Increases Thymic Stromal Lymphopoietin Expression in Keratinocytes – Quinn R. Roth-Carter

Oral Poster 3 Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited – Caroline A. Carpentier

Poster 1 Composition of Extracellular Matrix Microenvironment Dictates Phenotypic Plasticity, in situ Expansion, Maturation, and Survival of Tissue Eosinophils – Sergejs Berdnikovs

Poster 2 Eosinophils and Morphological Remodeling of the Esophageal Epithelium in Eosinophilic Esophagitis – Simon P. Hogan

Poster 3 Compartmentalization and Vesicular Trafficking of Interferon-Gamma (IFN-?) Within Human Eosinophils – Lívia A. S. Carmo

Poster 4 Rocks Negatively Regulate Secretion of Eosinophil Associated RNAES by Affecting CD11b Integrin – Revital Shamri
**Scientific Program**

**Thursday, 20 July 2017**

Poster 5 Characterization of a Novel Mouse Strain Expressing Human SIGLEC-8 Only on Eosinophils – Jeremy A. O’Sullivan

Poster 6 Characterizing a Novel Protein in Eosinophils: Nance-Horan Syndrome-Like Protein 2 (NHSL2) – Keren Turton

Poster 7 Regulation Of Eosinophil Granularity By Myb – Jessica E. Bolden

Poster 8 Mouse Eosinophil response to Lipopolysaccharide (LPS) Stimulation – Kennedy Bonjour

Poster 9 Benralizumab in hypereosinophilic syndromes: predictors of response – Fanny A. Legrand

Poster 10 Comparison of Eosinophil Adhesion and Migration Supported by TGF-BETA-Induced Protein (TGFBI) and Periostin Splice Variants – Mats W. Johansson

Poster 11 PI3K/MAPK Blockade Inhibits Eosinophil Extracellular Trap Cell Death – Shigeharu Ueki

Poster 12 For Whom the Eos Toll: Effect of Microenvironment on Murine Eosinophil Toll-Like Receptor Expression – Julia Krumholz

Poster 15 Eosinophil in a Three-Dimensional Collagen Gel in Vitro Have Decreased Surface L-Section (CD62L) – Mats W. Johansson, PhD

Poster 16 Manipulation of Mcl-1 critically alters mouse bone marrow-derived eosinophil apoptosis – Jennifer M. Felton

Poster 17 Adult Eosinophilic Esophagitis Patients’ Satisfaction with Different Disease-Specific Treatment Modalities – Ekaterina Safroneeva

Poster 18 Clinical picture and blood eosinophil phenotype of children with collagenous gastritis – Timo Käppi

Poster 19 Does The Grade Of T-Cell Infiltration Correlate With Eosinophil Counts Or Symptoms In Eosinophilic Esophagitis? – Helen Larsson

Poster 20 Initial Clinical Presentation of Patients with Hypereosinophilic Syndrome at a Tertiary Medical Center – Jay Jin

Poster 21 Evaluation of Eosinophil Biomarkers in Eosinophilic Esophagitis Patients – Evelyn L. Angulo

Poster 22 Eosinophilic Gastroenteritis Associated with Hirschsprung’s Disease and It’s Allied Disorders – Yoshiyuki Yamada

Poster 23 Eosinophilic Esophagitis risk variant at 2p23 dampens IL-13-induced calpain-14 promoter activity in a STAT6-dependent manner – Leah C. Kottyan

Poster 24 Down-regulated eosinophil activity in ulcerative colitis with concomitant primary sclerosing cholangitis – Maria Lampinen

**Friday, 21 July 2017**

**Session 4: Eosinophilic Differentiation and Effector Functions**

Moderators: Hans-Uwe Simon, Switzerland and Daniela Janevska Carroll, United States

8:00-8:30

State-of-the-Art: Eosinophil effector functions – Peter Weller, United States

8:30-9:00

State-of-the-Art: Molecular mechanisms regulating eosinophil granule protein release and toxicity – Hans-Uwe Simon, Switzerland
Scientific Program

Friday, 21 July 2017

9:00-9:30

Cutting Edge: Checkpoint inhibitory receptors on eosinophils – Ariel Munitz, Israel

9:30-9:45

Abstract Speaker: Trib1 regulates eosinophil identity by restraining the neutrophil identity program – Ethan Mack, United States

9:45-10:00

Abstract Speaker: Exosomes from eosinophils autoregulate and promote eosinophil functions – Victoria Del Pozo, Spain

10:00-10:30 - Coffee Break

Session 5: Eosinophils and Asthma

Moderators: Andrew Wardlaw, United Kingdom and Matthew Drake, United States

10:30-11:00

State-of-the-Art: Latest on eosinophils in asthma – Andrew Wardlaw, United Kingdom

11:00-11:30

Cutting Edge: The role of ILCs in regulating eosinophilic asthma – Roma Sehmi, Canada

11:30-12:00

Cutting Edge: The allergic effector unit: an eosinophil mast cell only pro-inflammatory cross-talk? – Francesca Levi-Schaffer, Israel

12:00-12:15

Abstract Speaker: Vacuolated eosinophils drive maladaptive immunity in experimental allergic asthma through the C5a-C5aR1 axis – Anna Valeska Wiese, Germany

12:15-12:30

Abstract Speaker: When is a wild type mouse not wild type? – Katie M Lebold, United States

12:30-12:45

Abstract Speaker: Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: a phase III randomized, placebo-controlled trial – Michael Wechsler, United States

12:45-15:00 - Conference Lunch, Meetings, Networking

Session 6: Eosinophils in Immune Regulation and Tissue Homeostasis

Moderators: Marie Carlson, Sweden and Lisa Spencer, United States

15:00-15:30

State-of-the-Art: Eosinophils as masters of T cell fate – Christine Wennerås, Sweden

15:30-16:00

State-of-the-Art: Eosinophils as mediators of local immune responses and remodeling – Sergejs Berdnikovs, United States

16:00-16:30

Cutting Edge: Eosinophils suppress Th2 responses in Peyer’s patches during nematode infection – Claudia Berek, Germany

16:30-16:45

Abstract Speaker: Single-cell Analysis of Human T cells in Eosinophilic Inflammation – Ting Wen, United States
Scientific Program

Friday, 21 July 2017

16:45-17:00
Abstract Speaker: IL-33 dysregulates regulatory T (Treg) cells and impairs established immunological tolerance in the lungs – Hirohito Kita, United States

17:00-17:15 – Coffee Break

Human Vs. Mouse Eosinophils – The Non-Battle of Eosinophils

Moderator: Christine Wennerås, Sweden

17:15-18.00
Pros and cons for elucidating mechanisms of asthma and allergic airways disease – William Busse, United States and Helene Rosenberg, United States

Moderators: Mats Johansson, United States, Josiane Neves, Brazil, Peter Weller, United States, Hirohito Kita, United States and Bruce Bochner, United States

18:00-20:00
Poster Session II (Mini-Oral Presentations, Poster Walkabouts, Drinks and finger foods)

Oral Poster 4 SIGLEC-8 is an Activating receptor on Human Eosinophils for Integrin-Dependent Adhesion, ROS Generation and Apoptosis – Daniela J. Carroll

Oral Poster 5 CD300F Inhibits Adipose Tissue Eosinophil Homing and Subsequent IL-4 Production by Regulating IL-5 Receptor Signaling – Perri Rozenberg

Oral Poster 6 Eosinophils Stimulate Airway Sensory Nerve Growth in Asthma – Matthew G. Drake

Poster 25 Pulmonary Eosinophils Increase Vagus Nerve Mediated Airway Reflex Response in Mice – Zhenying Nie

Poster 26 Eosinophils Regulate Airway Parasympathetic Nerve Ganglion Structure – Alexandra B. Pincus

Poster 27 Ozone and Sensitization Alter Tissue, Lavage and Nerve-Associated Eosinophils in the Lung – Matthew G. Drake

Poster 28 Focal Adhesion Kinase (FAK) Inhibition Blocks Eosinophil Recruitment in response to IL-4 In Vitro and In Vivo – Kamala D. Patel

Poster 29 Dexprimipexole effectively lowers blood and tissue eosinophils in subjects with chronic rhinosinusitis with nasal polyps – Calman Prussin

Poster 30 IL-3 Differentially Activates Eosinophils Compare to IL-5 and GM-CSF – Stephane Esnault

Poster 31 RNA-Sequencing Analysis of Lung Primary Fibroblast response to Eosinophil-Deregulation Products Predicts Downstream Effects on Inflammation, Tissue Remodeling and Lipid Metabolism – Stephane Esnault

Poster 32 Eosinophils Impair Airway Substance P Breakdown by Inhibiting Neutral Endopeptidase – Katie M. Lebold

Poster 33 Quantification of ‘Whole Lung’ Eosinophilic Inflammation in Asthma and Systemic Disease Using Radiolabelled Autologous Human Eosinophils – Neda Farahi

Poster 34 Increased Beige Fat and Eosinophil Infiltration in Mice Lacking Kruppel-Like Factor 3 (KLF3) – Alexander Knights

Poster 36 Local IL-5 Production by Bone Marrow ILC2s in IL-33-Driven Eosinophilia – Kristina Johansson

Poster 37 Eosinophils Secrete Galectin-10 Via Eosinophilic Extracellular Traps, Exosomes and Immune Synapses – Christine Lingblom

Poster 38 Clinical significance and antigenic specificity of anti-eosinophil autoantibodies – Régis Dieckmann
Scientific Program

Friday, 21 July 2017

Poster 39 Investigation of Natural Killer Cell–Mediated Eosinophil Apoptosis by Benralizumab – Roland Kolbeck
Poster 40 High Affinity IgE Receptor Enhances in vivo Antigen Presentation Capabilities of Airway Eosinophils – Haibin Wang
Poster 41 Potent EOS Adhesion with IL-33 Stimulation and Periostin as Substrate – Paul Fichtinger
Poster 42 Eosinophil Accumulation Oxazolone-Induced Atopic Dermatitis is Independent of IL-13 Receptor Alpha 1 – Almog Bitton
Poster 43 Eosinophil Persistence in the Airway Following Alternaria Inhalation Exposure – Caroline M. Percopo
Poster 44 Eosinophils and Altered Skin Barrier Function in Development of Food Allergy: Novel Mechanisms of Food Allergy – Joan M. Cook-Mills
Poster 45 Short chain fatty (SCFA) acids activate the intrinsic apoptosis pathway in eosinophils – Anna Theiler
Poster 46 I Will Survive: Lung Eosinophils Isolated From Allergen-Challenged Mice Display Prolonged Viability in the Absence of IL-5 – Wendy Geslewitz
Poster 47 Altered miR-155 Expression in Allergic Asthmatic Airways – Madeleine K. Radinger
Poster 48 Evaluation of immunohistopathologic and therapeutic effects of anti Siglec-F antibody in the lung of a mouse model of breast cancer and allergic asthma – Sima Shahmohammadi Farid
Poster 49 STAT6 AND SOCS3: Involvement in CCL26 Production by Bronchial Epithelial Cells in Asthma and It’s Severity – Marie-Chantal Larose

Saturday, 22 July 2017

Session 7: Eosinophils in Clonal Diseases - Autoimmunity and Malignancy

Moderators: Amy Klion, United States and Ariel Munitz, Israel

8:00-8:30
State-of-the-Art: How can we stop eosinophils from taking over – lessons from HES trials – Amy Klion, United States

8:30-9:00
Cutting Edge: Bullous pemphigoid – Christian Sadik, Germany

9:00-9:30
Cutting Edge: Eosinophils in clonal T cell malignancies – Florence Roufosse, Belgium

9:30-9:45
Abstract Speaker: Eosinophils are an integral part of the tumor microenvironment in colorectal cancer exerting potent anti-tumorigenic activities – Hadar Reichman, Israel

9:45-10:00
Abstract Speaker: Evidence for a role of eosinophils in blister formation in bullous pemphigoid – Dagmar Simon, Switzerland

10:00-10:30 – Coffee Break

Session 8: Eosinophils, Glycobiology and Metabolism

Moderators: Christine Wennerås, Sweden and Elizabeth Jacobsen, United States

10:30-11:00
State-of-the-Art: Galectin-10 – the mysterious auto-crystalizing protein – Steven Ackerman, United States
Scientific Program

Saturday, 22 July 2017

11:00-11:30
Cutting Edge: Eosinophil siglecs and their ligands – Bruce Bochner, United States

11:30-12:00
Cutting Edge: Eosinophils galectins and glycans – P. Sriramarao, United States

12:00-12:15
Abstract Speaker: Siglec-7 downregulates human eosinophil activation in vitro – Nadine Landolina, Israel

12:15-12:30
Abstract Speaker: Adipocytes support eosinophil migration and survival – Michal Itan, Israel

12:30-14:00 – Conference Lunch, Meetings, Networking

Session 9: Working with Eosinophils: Tools and Biomarkers
Moderators: Bruce Bochner, United States and Josiane Neves, Brazil

14:00-14:30
State-of-the-Art: Laboratory techniques and resources for murine eosinophils – Elizabeth Jacobsen, United States

14:30-15:00
State-of-the-Art: Laboratory techniques and resources for human eosinophils – Lisa Spencer, United States

15:00-15:30
Cutting Edge: New mechanisms in IBD therapies – the mucosa under attack. What about the eosinophils? – Henit Yanai, Israel

15:30-15:45
Abstract Speaker: The role of autophagy in eosinophils – Nina Germic, Switzerland

15:45-16:00
Abstract Speaker: Haemosphere: A web-portal to delight immunologists and hematologists alike – Kirsten Fairfax, Australia

16:00-16:15 – Coffee Break

Battle of Eosinophilosophers – Is the Eosinophil a Good Guy or Bad Guy?
Moderator: Marie Carlson, Sweden
16:15-16:45
Good Guy Team: Seema Aceves, United States – Bad Guy Team: Allison Fryer, United States

A Memorial Congregation in Honor of Jamie Lee, PhD
Moderators: Helene Rosenberg, United States and Peter Weller, United States
Open to discussion from audience
16:45-17:30
Ehrlich Lectureship – In honor of Jamie Lee

19:00-23:00 – Conference Dinner and Boat Ride
Scientific Program

Sunday, 23 July 2017

Session 10: Eosinophilomics and Eosinophils Moving Forward

Moderators: Madeleine Rådinger, Sweden and Sergejs Berdnikovs, United States

9:00-9:30  
State-of-the-Art: What I need to Know About Eosinophils and Transcription Factors – Patricia Fulkerson, United States

9:30-09:45  
Abstract Speaker: Characterizing a leukocyte-specific RHO guanine nucleotide exchange factor proteoform in eosinophils – Keren Turton, United States

09:45-10:15 – Coffee Break

Moderators: Florence Rofousse, Belgium

10:15-11:00  
Panel Discussion: Where we were, where are we now, and where we are going – Per Venge, Sweden, Andrew Wardlaw, United Kingdom, Seema Aceves, United States and Helene Rosenberg, United States

11:00-12:00  
Acknowledgements, Final Awards and Adjournment – Marie Carlson, Sweden and Christine Wennerås, Sweden
Gleich Award

Recipient of the 2017 Gleich Award

Dr. Claire Mesnil will receive the fourth Gerald J. Gleich prize to be awarded at the 10th Biennial Symposium of the International Eosinophil Society, Inc. in Gothenburg, Sweden. The prize was specifically created to recognize individuals who have published high impact findings during the intervals since the preceding meeting. This award was named in honor of our esteemed colleague, Dr. Gerald J. Gleich, whose career has been devoted to the exploration of the eosinophilic leukocyte and to the elucidation of its role in health and disease. The prize is bestowed by a consulting committee and Dr. Gerald J. Gleich.

LUNG-RESIDENT EOSINOPHILS REPRESENT A DISTINCT REGULATORY EOSINOPHIL SUBSET

Claire Mesnil,1,2 Stéfanie Raulier,1 Geneviève Paulissen,1 Xue Xiao,2,3 Mark A. Birrell,4 Dimitri Pirottin,1,2 Thibaut Janss,1 Philipp Starkl,1 Eve Ramery,2 Monique Henket,2,7 Florence N. Schleich,6,1 Marc Radermecker,6 Kris Thielemans,2 Laurent Gillet,2,3 Marc Thiry,1,6 Maria G. Belvisi,4 Renaud Louis,1,2 Christophe Desmet,1,2 Thomas Marichal,1,2 and Fabrice Bureau1,2,11

1Laboratory of Cellular and Molecular Immunology, Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA) Research, 2Faculty of Veterinary Medicine, and 3Immunology-Vaccinology, Fundamental and Applied Research for Animals and Health, University of Liège, Liège, Belgium. 4Respiratory Pharmacology, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom. 5CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, and Department of Medicine I, Medical University of Vienna, Vienna, Austria. 6Department of Pulmonary Medicine, 7Laboratory of Pneumology, GIGA Research, and 8Department of Cardiovascular and Thoracic Surgery and Human Anatomy, Centre Hospitalier Universitaire (CHU), University of Liège, Liège, Belgium. 9Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium. 10Laboratory of Cellular and Tissular Biology, GIGA Research, University of Liège, Liège, Belgium. 11Walloon Excellence in Lifesciences and Biotechnology (WELBIO), Wallonia, Belgium.

A Memorial Congregation in Honor of Jamie Lee, PhD

Recipient of the 2017 Ehrlich Lectureship

*as printed in April JACI

In lasting tribute: Dr. James J. Lee (1958-2017)

It is with deep sorrow that we report the untimely death of our friend and colleague Dr. James (Jamie) Lee, who passed away on Saturday, March 25, 2017, at his home in Scottsdale, Arizona.

Originally from Long Island, New York, Dr. Lee received a BS in Biochemistry from the State University of New York at Stony Brook. After graduate studies with Dr. Eric Davidson at Caltech and postdoctoral studies at Columbia University, he joined the staff at Mayo Clinic Arizona, where he held the position of Professor of Biochemistry and Molecular Biology in the Division of Pulmonary Medicine. In collaboration with his wife and lifelong research partner, Dr. Nancy A. Lee, the long-term focus of Dr. Lee’s work has been improving our understanding of how eosinophilic leukocytes contribute to the pathogenesis of allergy, asthma, and cancer.

Dr. Lee has led by example in being a strong advocate of collaboration and service to the scientific community. Without doubt, among Dr. Lee’s finest contributions to eosinophil biology are a unique series of transgenic and gene-deleted mice. The first of these mice, NJ.1638, include the IL-5 transgene expressed under the control of the T-cell CD3d promoter that results in massive systemic eosinophilia. The Lee laboratories also created TgPHIL and iPHIL, both eosinophil-deficient models that use the eosinophil peroxidase promoter to facilitate lineage depletion. Use of these mouse models in the Lee laboratories and many others have transformed our understanding of the importance of eosinophils in a range of immune responses. Dr. Lee was particularly interested in the concept of eosinophils as key mediators of immune regulation and tissue remodeling. Most recently, the Lees and colleagues introduced eoCre, which also uses the eosinophil peroxidase gene promoter to direct expression of Cre recombinase, resulting in a means to generate eosinophil-specific gene deletions. Together with his development of gold-standard reagents, such as antibodies recognizing eosinophil granule proteins, eosinophil biology has grown and flourished in no small part because of the generosity of the Lee laboratories.

Dr. Lee has held many important posts and responsibilities, including past President of the International Eosinophil Society, where he also served on the Board of Directors. He was a member of the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases and served as Co-Editor in Chief for the multi-author text Eosinophils in health and disease (Elsevier, 2012).

Dr. Lee was scheduled to receive the 2017 Paul Ehrlich Award this coming July, the highest award bestowed on a colleague who has made seminal scientific contributions to research on the eosinophil and related allergy/immunology fields by the members of the International Eosinophil Society.

It is difficult to convey fully the effect of the loss of a member of our close-knit research family. We will always remember Jamie, and we will be inspired by his exuberant sense of humor, boundless energy, extraordinary creativity, and unwavering commitment to the scientific community.

*Helen F. Rosenberg, MD, PhD
Elizabeth A. Jacobson, PhD
Bruce Bochner, MD
Peter F. Weller, MD

Paul Ehrlich Lectureship
International Eosinophil Society, Inc.
2017

James J. Lee, MD

For seminal work in the field of eosinophil immunobiology and physiology and outstanding contributions to the understanding of the role of eosinophils in health and disease.
Recipient of the 2017 International Eosinophil Society Service Award

The International Eosinophil Society, Inc., its leaders and members present to Dr. Peter F. Weller the distinguished Service Award both for his cardinal leadership with the International Eosinophil Society, Inc. and for his career-long contributions to innovative studies of the immunobiology of eosinophils.

Peter F. Weller, M.D., MACP, the William Bosworth Castle Professor of Medicine at Harvard Medical School, is Chief of both the Division of Infectious Diseases and the Division of Allergy and Inflammation at Beth Israel Deaconess Medical Center, Harvard Medical School. He is also a Professor of Immunology and Infectious Diseases at the Harvard Chan School of Public Health. Dr. Weller received his M.D. from Harvard Medical School and completed his medicine training at the Peter Bent Brigham Hospital, his infectious diseases training at the Laboratory of Parasitic Diseases, National Institutes of Health and at Massachusetts General Hospital, and his allergy training at the Brigham and Women’s Hospital. He is board-certified in Internal Medicine, Infectious Diseases and Allergy and Immunology.

Dr. Weller’s research studies, supported by longstanding NIH grants, have focused on delineating mechanisms of leukocyte functioning, including a major focus on the immunobiology of eosinophilic leukocytes. Of his over three dozen trainees, most have senior academic positions nationally and internationally. Dr. Weller’s clinical areas of interest and expertise include parasitic infectious diseases and allergic diseases, including eosinophil-associated syndromes and diseases. In these areas, he has a record of continuing contributions, including over 450 publications.

With Dr. Weller’s career long interest in eosinophils, he along with others, including the late Redwan Moqbel, shepherded the coalesce of common eosinophil interests amongst our international community to lead to the formation of the International Eosinophil Society and its maturation into fully active Society. Dr. Weller has served as the Secretary-Treasurer of the International Eosinophil Society and currently is the President of the Society.
Save the Date

Portland
Oregon
9-13 July 2019
IES thanks the following partners for their support of the 10th Biennial Symposium

Gold Supporter

Silver Supporters

AstraZeneca

Diagnostics Development

Bronze Supporters

Allakos

Apfed

CURED

Knopp Biosciences

Additional Support

Novartis Institutes for BioMedical Research, Inc.

Society Sponsors

American Academy of Allergy, Asthma & Immunology

Society for Leukocyte Biology

Journal of Leukocyte Biology

Grant Support

National Institutes of Health

Funding for this conference was made possible in part by 1 R13 AI 131485 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.